In vitro activity of the synthetic lipopeptide Pal-Lys-Lys-NH2 alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans
Barchiesi, F.; Giacometti, A.; Cirioni, O.; Arzeni, D.; Siluestri, C.; Kamysz, W.; Abbruzzetti, A.; Riua, A.; Kamysz, E.; Scalise, G.
Peptides (New York, Ny 1980) 28(8): 1509-1513
2007
ISSN/ISBN: 0196-9781 Accession: 075875170
PDF emailed within 1 workday: $29.90
Related References
Barchiesi, F.; Giacometti, A.; Cirioni, O.; Arzeni, D.; Silvestri, C.; Kamysz, W.; Abbruzzetti, A.; Riva, A.; Kamysz, E.; Scalise, G. 2007: In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans Peptides 28(8): 1509-1513Kamysz, E.; Simonetti, O.; Offidani, A.; Barchiesi, F.; Cirioni, O.; Arzeni, D.; Ganzetti, G.; Campanati, A.; Giacometti, A.; Gabrielli, E.; Silvestri, C.; Kamysz, W. 2011: In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp Peptides (New York, Ny 1980) 32(1): 99-103
Kamysz, E.; Simonetti, O.; Cirioni, O.; Arzeni, D.; Ganzetti, G.; Campanati, A.; Giacometti, A.; Gabrielli, E.; Silvestri, C.; Kamysz, W.; Offidani, A.; Barchiesi, F. 2011: In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp Peptides 32(1): 99-103
Simonetti, O.; Arzeni, D.; Ganzetti, G.; Silvestri, C.; Cirioni, O.; Gabrielli, E.; Castelletti, S.; Kamysz, W.; Kamysz, E.; Scalise, G.; Offidani, A.; Barchiesi, F. 2009: In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes British Journal of Dermatology 161(2): 249-252
Simonetti, O.; Arzeni, D.; Offidani, A.; Barchiesi, F.; Ganzetti, G.; Silvestri, C.; Cirioni, O.; Gabrielli, E.; Castelletti, S.; Kamysz, W.; Kamysz, E.; Scalise, G. 2009: In vitro activity of the lipopeptide derivative (Pal-lys-lys-NH2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes British Journal of Dermatology (1951) 161(2): 249-252
Illnait-Zaragozi, M.-T.; Martínez, G.F.; Curfs-Breuker, I.; Fernández, C.M.; Boekhout, T.; Meis, J.F. 2008: In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba Antimicrobial Agents and ChemoTherapy 52(4): 1580-1582
De Bedout, C.; Ordóñez, N.; Gómez, B.L.; Rodríguez, M.C.; Arango, M.; Restrepo, A.; Castañeda, E. 1999: In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii Revista Iberoamericana de Micologia 16(1): 36-39
Yildiran, S.T.; Saracli, M.A.; Fothergill, A.W.; Rinaldi, M.G. 2000: In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole European Journal of Clinical Microbiology and Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 19(4): 317-319
Barchiesi, F.; Giacometti, A.; Cirioni, O.; Arzeni, D.; Kamysz, W.; Silvestri, C.; Licci, A.; Marigliano, A.; Della Vittoria, A.; Nadolski, P.; Łukasiak, J.; Scalise, G. 2007: In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp Journal of ChemoTherapy 19(5): 514-518
Tay, S.T.; Tanty Haryanty, T.; Ng, K.P.; Rohani, M.Y.; Hamimah, H. 2006: In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs Mycoses 49(4): 324-330
Long-Feng; Zhang-Yong-Xin; Li-Ming; Zhang-Qiang-Qiang; Wang-Jia-Jun 2002: In-vitro susceptibility of 248 isolates of Candida sp. and Cryptococcus neoformans to four antifungal agents Zhongguo Kangshengsu Zazhi 27(5): 305-308
Al-Odaini, N.; Li, X.-Y.; Li, B.-K.; Chen, X.-C.; Huang, C.-Y.; Lv, C.-Y.; Pan, K.-S.; Zheng, D.-Y.; Zheng, Y.-Q.; Liao, W.-Q.; Cao, C.-W. 2021: In vitro Antifungal Susceptibility Profiles of Cryptococcus neoformans var. grubii and Cryptococcus gattii Clinical Isolates in Guangxi, Southern China Frontiers in Microbiology 12: 708280
Vitale, R.G.; Pascuccelli, V.; Afeltra, J. 2012: Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains Journal of Medical Microbiology 61(Part 3): 384-388
Chen-Tao; Lu-Ting-Li; Zhang-Yan; Fu-Jing-Guo 2007: In vitro antifungal activity of synthetic cationic polyethylenimine alone and in combination with three conventional antimicrobial agents against Candida albicans clinical isolates Zhongguo Kangshengsu Zazhi 32(8): 511-S3
Chowdhary, A.; Randhawa, H.Singh.; Sundar, G.; Kathuria, S.; Prakash, A.; Khan, Z.; Sun, S.; Xu, J. 2011: In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India Journal of Medical Microbiology 60(Pt 7): 961-967
Kontoyiannis, D.P.; Lewis, R.E.; Alexander, B.D.; Lortholary, O.; Dromer, F.ço.; Gupta, K.L.; John, G.T.; Del Busto, R.; Klintmalm, G.B.; Somani, J.; Lyon, G.M.; Pursell, K.; Stosor, V.; Munoz, P.; Limaye, A.P.; Kalil, A.C.; Pruett, T.L.; Garcia-Diaz, J.; Humar, A.; Houston, S.; House, A.A.; Wray, D.; Orloff, S.; Dowdy, L.A.; Fisher, R.A.; Heitman, J.; Albert, N.D.; Wagener, M.M.; Singh, N. 2008: Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis Antimicrobial Agents and ChemoTherapy 52(2): 735-738
Abdel-Salam, H.A. 2005: In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs Mycoses 48(5): 327-332
Franzot, S.P.; Hamdan, J.S. 1996: In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs Antimicrobial Agents and ChemoTherapy 40(3): 822-824
Perkins, A.; Gomez-Lopez, A.; Mellado, E.; Rodriguez-Tudela, J.L.; Cuenca-Estrella, M. 2005: Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans Journal of Antimicrobial ChemoTherapy 56(6): 1144-1147
Guo XiuJun; Liao WanQing; Ren DaMing; Xu Hong 2003: In vitro study of combination of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans Journal of Clinical Dermatology 32(8): 444-446